靶向药物曲妥珠单抗联合化疗对人类表皮生长因子受体2阳性局部晚期乳腺癌患者临床疗效研究

摘要/Abstract

摘要： 目的: 观察曲妥珠单抗联合化疗对人类表皮生长因子受体2(HER-2)阳性的局部晚期乳腺癌(LABC)临床治疗结果。方法: 将228例HER-2阳性手术无法切除的晚期乳腺癌病例随机分到曲妥珠单抗辅助疗法+化疗组或单纯化疗组。其中115例接受曲妥珠单抗+化疗,113例单纯接受化疗,经过10个疗程治疗后,观察两组患者中临床和病理的完全缓解人数及符合手术要求的人数。结果: 数据显示与单纯化疗相比,曲妥珠单抗+化疗组病例对治疗的临床完全缓解病例(cCR)(化疗+曲妥珠单抗组89%,单纯化疗组77%)、病理学完全缓解(pCR)病例(两组分别为43%和23%)以及乳房和腋下淋巴结完全缓解(tpCR)病例(分别为39%和20%)比例更高,同时可以使更多的患者获得手术和保留乳房的机会。结论: 曲妥珠单抗联合化疗药物治疗HER-2过度表达的局部晚期乳腺癌均有较好的临床疗效,是治疗晚期乳癌并延长生存时间的一种新方法。

关键词: 曲妥珠单抗, 局部晚期乳腺癌, 化疗

Abstract: AIM: To observe the efficacy of trastuzumab in treating patients with HER-2 positive locally advanced breast cancer (LABC). METHODS: 228 HER-2 positive patients with unresectable locally advanced breast cancer patients were randomly divided into 2 groups. 115 patients received trastuzumab plus chemotherapy, 113 cases received chemotherapy alone. After 10 courses of treatment, the number of clinical and pathology complete remission and potentially eligible for surgery patients were observed. RESULTS: Compared with chemotherapy group, trastuzumab plus chemotherapy group had more higher proportion in complete remission(cCR)(89% in trastuzumab plus chemotherapy group and 77% in chemotherapy group), pathological complete response(pCR)(43% and 23% respectively) and breast and axillary lymph node complete remission(tpCR)(respectively 39% and 20%). Trastuzumab plus chemotherapy group had more chance to surgery and breast conservation. CONCLUSION: Trastuzumab combined with chemotherapy is an effective schedule in the treatment of HER-2 positive locally advanced breast.

Key words: trastuzumab, breast cancer, chemotherapy

中图分类号:

袁宏钧. 靶向药物曲妥珠单抗联合化疗对人类表皮生长因子受体2阳性局部晚期乳腺癌患者临床疗效研究[J]. 中国临床药理学与治疗学, 2015, 20(1): 86-90.

YUAN Hong-jun. Clinical effect of trastuzumab combined chemotherapy in patients with HER-2 positive locally advanced breast cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 86-90.

参考文献

[1] Mehta RS, Schubbert T, Kong K. Trastuzumab in inflammatory breast cancer[J]. Ann Oncol, 2008, 19(10): 1815-1817.
[2] 郭小毛, 梅欣, 章倩. 局部晚期乳腺癌的治疗进展[J]. 中国癌症杂志, 2006, 16(6): 409-415.
[3] Dawood S, Gong Y, Broglio K, et al. Trastuzumab in primary inflammatory breast cancer (IBC): high pathological response rates and improved outcome[J]. Breast J, 2010[Epub ahead of print].
[4] Kaufman B, Trudeau M, Awada A, et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study[J]. Lancet Oncol, 2009, 10(6): 581-588.
[5] Boussen H, Cristofanilli M, Zaks T, et al. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer[J]. J Clin Oncol, 2010, 28(20): 3248-3255.
[6] Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort[J]. Lancet, 2010, 375(9712): 377-384.
[7] 胡升芳, 陈红风, 陆德铭. HER-2过表达乳腺癌治疗研究进展[J]. 中华中医药学刊, 2011, 29(3): 560-562.
[8] 易敏. 曲妥单抗联合多西紫杉醇和卡培他滨治疗晚期转移性乳腺癌[J]. 中国医药指南, 2012, 10(15): 568-570.
[9] Dawood S, Broglio K, Kau SW, et al. Prognostic value of initial clinical disease stage after achieving pathological complete response[J]. Oncologist, 2008, 13(1): 6-15.
[10] Bristol IJ, Woodward WA, Strom EA, et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer[J]. Int J Radiat Oncol Biol Phys, 2008, 72(2): 474-484.
[11] Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial[J]. Lancet, 2007, 369(9555): 29-36.
[12] Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer[J]. J Clin Oncol, 2010, 28(6): 976-983.

[1]	王如玥, 谢飞, 王欣, 李红玉. 脾多肽注射液对化疗后KM小鼠骨髓抑制和免疫力低下的治疗作用[J]. 中国临床药理学与治疗学, 2023, 28(9): 1000-1007.
[2]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[3]	李爽, 韩淑贞, 戴瑜婷, 修明慧, 杜籼芹, 和建政, 蔺兴遥. 基于多种化疗肠损伤发生机制的中医药防治进展[J]. 中国临床药理学与治疗学, 2023, 28(5): 583-593.
[4]	吴蓉蓉, 陈智强, 贾翼菲, 陈宏绮, 王盼盼, 燕茹. 靶向抑制肠道菌β-葡萄糖醛酸苷酶在肿瘤预防和治疗中的应用[J]. 中国临床药理学与治疗学, 2021, 26(8): 964-974.
[5]	鲁琼, 朱海宏, 戚听听, 李国华, 滕欣琪, 屈强, 屈健. OCTN2基因多态性影响结直肠癌奥沙利铂化疗敏感性[J]. 中国临床药理学与治疗学, 2021, 26(4): 401-407.
[6]	赵全凤, 符佩姝, 谷文睿, 郑丹, 吕宗杰, 杨洋. GnRHa用于化疗后生育力保护的循证医学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(12): 1449-1454.
[7]	田亚丽, 奉林, 赵万, 谷敏, 沈涵菁, 柴晓艳. BRCA1基因多态性与转移性食管鳞癌顺铂联合卡培他滨化疗敏感性及预后关系[J]. 中国临床药理学与治疗学, 2021, 26(10): 1118-1126.
[8]	张德志, 刘猛, 朱少功, 刘桂举, 季节. XELOX方案对比卡培他滨单药方案在老年结直肠癌患者术后辅助化疗中的疗效及安全性探讨[J]. 中国临床药理学与治疗学, 2020, 25(8): 926-936.
[9]	赵文超, 邱艳芳, 谭嵘. 肿瘤治疗中靶向DNA损伤反应[J]. 中国临床药理学与治疗学, 2020, 25(8): 943-952.
[10]	唐慕菲, 沈芸竹, 张保国. CYP2D6基因多态性对托烷司琼预防化疗所致恶心呕吐效果的影响[J]. 中国临床药理学与治疗学, 2020, 25(7): 817-822.
[11]	赵妙惠，周佳妮，漆勇. 桑黄多糖调控PI3K/AKT/mTOR通路抑制肝癌腹水荷瘤小鼠及对化疗的减毒增效作用[J]. 中国临床药理学与治疗学, 2020, 25(4): 401-407.
[12]	潘露萍，石武杰，沈志鹏. 依托泊苷联合卡铂用于复发性髓母细胞瘤患儿的疗效与安全性[J]. 中国临床药理学与治疗学, 2020, 25(2): 189-195.
[13]	马培敏，付毓，Marcus VETTER. HER2阳性乳腺癌辅助治疗中帕妥珠单抗和曲妥珠单抗的个体化给药研究[J]. 中国临床药理学与治疗学, 2020, 25(1): 9-21.
[14]	徐伟平，周维英. 膀胱癌化疗药物增敏机制研究进展[J]. 中国临床药理学与治疗学, 2019, 24(9): 1060-1064.
[15]	李荣振，梅家转，夏云展，季节. 真实世界中R0切除术后结直肠癌患者接受卡培他滨为基础辅助化疗的预后影响因素及安全性探讨[J]. 中国临床药理学与治疗学, 2019, 24(6): 704-711.